BGLC Key Statistics, Chart & Performance
The current stock price of BGLC is 3.9 USD. In the past month the price decreased by -8.45%. In the past year, price increased by 19.27%.
BGLC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| URI | UNITED RENTALS INC | 21.54 | 59.06B | ||
| GWW | WW GRAINGER INC | 26 | 49.13B | ||
| FAST | FASTENAL CO | 39.07 | 47.99B | ||
| FERG | FERGUSON ENTERPRISES INC | 22.19 | 44.96B | ||
| FTAI | FTAI AVIATION LTD | 54.52 | 24.49B | ||
| QXO | QXO INC | 98.6 | 16.62B | ||
| WSO | WATSCO INC | 28.18 | 14.63B | ||
| WSO.B | WATSCO INC -CL B | 26.47 | 13.74B | ||
| WCC | WESCO INTERNATIONAL INC | 21.1 | 13.02B | ||
| CNM | CORE & MAIN INC-CLASS A | 20.48 | 10.88B | ||
| AIT | APPLIED INDUSTRIAL TECH INC | 25.47 | 9.98B | ||
| AL | AIR LEASE CORP | 10.06 | 7.18B |
Related stock screener links
About BGLC
Company Profile
BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2020-03-11. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.
Company Info
BIONEXUS GENE LAB CORP
10-2 Tower B, Vertical Business Suite, 8 Jalan Kerinchi
KUALA LUMPUR WILAYAH PERSEKUTUAN MY
Employees: 30
Phone: 13072416898
BIONEXUS GENE LAB CORP / BGLC FAQ
What does BGLC do?
BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2020-03-11. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.
Can you provide the latest stock price for BIONEXUS GENE LAB CORP?
The current stock price of BGLC is 3.9 USD. The price decreased by -2.74% in the last trading session.
Does BIONEXUS GENE LAB CORP pay dividends?
BGLC does not pay a dividend.
How is the ChartMill rating for BIONEXUS GENE LAB CORP?
BGLC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of BIONEXUS GENE LAB CORP (BGLC)?
BIONEXUS GENE LAB CORP (BGLC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.28).
What is the market capitalization of BGLC stock?
BIONEXUS GENE LAB CORP (BGLC) has a market capitalization of 9.20M USD. This makes BGLC a Nano Cap stock.
BGLC Technical Analysis
BGLC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BGLC. While BGLC has a great health rating, there are worries on its profitability.
BGLC Financial Highlights
Over the last trailing twelve months BGLC reported a non-GAAP Earnings per Share(EPS) of -1.28. The EPS decreased by -220.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.14% | ||
| ROE | -33.7% | ||
| Debt/Equity | 0 |